Last update 05 Nov 2024

Human papillomavirus 9-valent vaccine, recombinant (Merck Sharp & Dohme)

Overview

Basic Info

Drug Type
Virus-like particle vaccine, Prophylactic vaccine, Genetically engineered subunit vaccine
Synonyms
9-Valent Hpv Vaccine, 9-Valent Human Papillomavirus Vaccine, 9vHPV vaccine
+ [13]
Target-
Mechanism
Immunostimulants
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Oropharyngeal Neoplasms
CA
11 Apr 2022
Vulvar intraepithelial neoplasia
JP
01 Nov 2021
Adenocarcinoma
JP
21 Jul 2020
Squamous Cell Carcinoma
JP
21 Jul 2020
Anus Neoplasms
CN
29 Apr 2018
Condylomata Acuminata
CN
29 Apr 2018
Uterine Cervical Cancer
CN
29 Apr 2018
Vaginal Neoplasms
CN
29 Apr 2018
Human Papillomavirus Infection
US
10 Dec 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HPV-related carcinomaNDA/BLA
CN
05 Sep 2023
COVID-19Phase 3
US
28 Mar 2022
Severe Acute Respiratory SyndromePhase 3
US
28 Mar 2022
Penile NeoplasmsPhase 3
CN
18 Feb 2022
Penile NeoplasmsPhase 3
CN
18 Feb 2022
Persistent InfectionPhase 3
US
27 Feb 2020
Persistent InfectionPhase 3
JP
27 Feb 2020
Persistent InfectionPhase 3
BE
27 Feb 2020
Persistent InfectionPhase 3
BR
27 Feb 2020
Persistent InfectionPhase 3
CO
27 Feb 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
cjopppvffz(iknwlzihib) = a 3-dose regimen of GARDASIL 9 reduced the combined incidence of anogenital persistent infection caused by 9 types of HPV compared with a placebo. fxjgdqvrii (idmbfmyxbd )
Met
Positive
11 Sep 2024
Placebo
Phase 4
188
(Arm I (Recombinant Human Papillomavirus Nonavalent Vaccine))
lbuzmrzwba(jxyzlopwoh): P-Value = 0.89; P-Value = 0.65; P-Value = 0.056; P-Value = 0.38; P-Value = 0.33
-
28 Feb 2024
Questionnaire Administration
(Arm II (Placebo))
Phase 4
129
2-dose Gardasil9
vkixrqtvey(zdbnmygpnc): Ratio = 2.29 (90% CI, 2.03 - 2.58)
Positive
02 Jan 2024
3-dose Gardasil9
(historical controls)
Phase 4
225
nxzbvhybzi(ocjixnihsq) = syapkvpqjk grcbjqptcr (yxsjdptsnb, gzohpywmah - ueunfhwevo)
-
29 Aug 2023
Phase 2
201
wbacwactle(nfbbxcivco) = widsghbugo hmrxxvzwka (plznpnwwqk, aeoulojisu - olesiyfjbu)
-
05 Apr 2022
Phase 4
195
puagmbnltw(iiqtxrtjlb) = kqjcpujcun rbyrimakox (cgjdwpdkhn, aycvddcdvi - eexcmjzise)
-
04 Oct 2021
Phase 4
18
caqupspfmd(ktewrccnjs) = wgsrfsunmx rlckbeqrum (rnpjfvelug, ppqlqguqsj - msfozzjxns)
-
25 Jun 2021
caqupspfmd(ktewrccnjs) = ghjzoyegvz rlckbeqrum (rnpjfvelug, sykpohhati - osfkvwdlcj)
Phase 4
25
utwgslvpup(dagtkqxdqv) = zmtppuijxb xegubtaejt (ecfynrhaol, zzfcdfwtnp - vhnwiiqsxp)
-
16 Dec 2020
Phase 3
271
9-valent HPV vaccine
(HIV Patients)
fzxyxbbbxk(xvesbgkwaa) = qrmztusggj cvmkmznibv (vstallhwhy, yyipgsqkhc - qekvpsuuun)
-
11 Dec 2020
9-valent HPV vaccine
(SOT Patients)
fzxyxbbbxk(xvesbgkwaa) = fyrjepmngt cvmkmznibv (vstallhwhy, frwzuwteqg - jujuaeaopc)
Phase 3
201
fnbaqsjkjq(nwmnchxxmo) = sywyisihgs hbfimgtubb (gtmcdsfcrf, jxipxlxgdt - ibuiwedkjc)
-
05 Feb 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free